A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer
Connie D. Cao, Joseph Robert McCorkle, Donglin Yan, Hoda Saghaeiannejad Esfahani et autres
0 citationsCancers
Frederick R. Ueland
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
159Publications signalées
5090Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer TreatmentsUterine Myomas and TreatmentsBRCA gene mutations in cancerIntraperitoneal and Appendiceal Malignancies
Publications récentes
A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer
Connie D. Cao, J. Robert McCorkle, Donglin Yan, Hoda Saghaeiannejad Esfahani et autres
0 citationsPreprints.org
PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240
Angeles Alvarez Secord, Michael W. Sill, Heather A. Lankes, Michael J. Birrer et autres
0 citationsInternational Journal of Gynecological Cancer
Focal Adhesion Kinase Intersects With the BRD4‐MYC Axis and YAP1 to Drive Tumor Cell Growth, Phenotypic Plasticity, Stemness, and Metastatic Potential in Colorectal Cancer
Rongbo Han, Junfeng Shi, Kai Cheng, Zian Wang et autres
5 citationsCancer Medicine
Phase I dose escalation of ArtemiCoffee in women with advanced ovarian cancer
Connie D. Cao, Donglin Yan, Lauren Baldwin, Rachel W. Miller et autres
0 citationsGynecologic Oncology
1073P 5-year progression-free survival (PFS) with rucaparib (RUCA) maintenance in patients with newly diagnosed advanced ovarian cancer in ATHENA-MONO (GOG-3020/ENGOT-ov45)
Rebecca Kristeleit, Sharad Ghamande, A.S. Lisyanskaya, A. Oaknin et autres
0 citationsAnnals of Oncology
M1 macrophage-engineered vesicles have anti-cancer activity in ovarian cancer
Connie D. Cao, J. Robert McCorkle, Derek B. Allison, Donglin Yan et autres
1 citationCancer Nanotechnology
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study
Victoria Bae‐Jump, Michael W. Sill, Paola A. Gehrig, Jason D. Merker et autres
11 citationsGynecologic Oncology
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258
Aine Clements, Danielle Enserro, Kyle C. Strickland, Rebecca A. Previs et autres
23 citationsGynecologic Oncology
Molecular Classification of Endometrial Cancers (EC) and Association with Relapse-Free Survival (RFS) and Overall Survival (OS) Outcomes: Ancillary Analysis of GOG-0258
Aine Clements, Danielle Enserro, Kyle C. Strickland, Rebecca A. Previs et autres
0 citationsSSRN Electronic Journal
Comparison of the Clinical and Genomic Profiles of Endometrial Cancer in Appalachian and Non-Appalachian Patients
Taylor Rives, Abu Saleh Mosa Faisal, Jinpeng Lui, Hye Sook Chon et autres
0 citationsSSRN Electronic Journal
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
Daniela Matei, Danielle Enserro, Marcus E. Randall, David G. Mutch et autres
11 citationsJournal of Clinical Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.